AI platform to unlock new classes of anti-sense oligonucleotide therapies.

TORONTO, Ontario, Canada, September 25, 2017 - Deep Genomics, the leading AI therapeutics company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by ...

Brendan Frey, the chief executive, studied under Mr. Hinton at the University of Toronto, and he has spent years on research that combines deep-learning A.I. and cell biology. When he hires software engineers, he asks them to make multiyear commitments. “There are a lot ...

Artificial intelligence is already powering your Google searches, your Netflix recommendations, and your smartphone’s virtual assistant. It is playing humans at complex, intuitive games like Go, and it is beating them. Now, researchers say, they want AI to power your doctor’s diagnoses, your ...

Deep learning has already had a huge impact on computer vision and speech recognition, and it's making inroads in areas as computer-unfriendly as cooking. Now a new startup led by University of Toronto professor Brendan Frey wants to cause similar reverberations in genomic medicine ...

With frustration fresh on his mind, Frey knew he wanted to work on genomics. Out of hardship, Frey sought a way to make a positive impact, and his deep learning background would be his secret weapon. “How can I make a difference to the next ...

Deep Genomics, a fresh new University of Toronto spinout, is combining deep machine learning techniques with artificial intelligence to study the human genome... “We use machine learning to try to mimic the way in which the cell works – and predict whether a person will get ...